These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18706698)

  • 1. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
    Leung LL; Myles T; Nishimura T; Song JJ; Robinson WH
    Mol Immunol; 2008 Oct; 45(16):4080-3. PubMed ID: 18706698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI).
    Leung LL; Nishimura T; Myles T
    Adv Exp Med Biol; 2008; 632():61-9. PubMed ID: 19025114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo.
    Nishimura T; Myles T; Piliponsky AM; Kao PN; Berry GJ; Leung LL
    Blood; 2007 Mar; 109(5):1992-7. PubMed ID: 17105819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation.
    Myles T; Nishimura T; Yun TH; Nagashima M; Morser J; Patterson AJ; Pearl RG; Leung LL
    J Biol Chem; 2003 Dec; 278(51):51059-67. PubMed ID: 14525995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activatable fibrinolysis inhibitor.
    Marx PF
    Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).
    Bouma BN; Meijers JC
    J Thromb Haemost; 2003 Jul; 1(7):1566-74. PubMed ID: 12871292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F; Ammollo CT; Gils A; Declerck PJ; Colucci M
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)].
    Urano T
    Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
    Morser J; Gabazza EC; Myles T; Leung LL
    J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor.
    Plug T; Meijers JC
    J Thromb Haemost; 2016 Apr; 14(4):633-44. PubMed ID: 26786060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
    Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
    J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis.
    Van de Wouwer M; Plaisance S; De Vriese A; Waelkens E; Collen D; Persson J; Daha MR; Conway EM
    J Thromb Haemost; 2006 Aug; 4(8):1813-24. PubMed ID: 16879225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation of thrombin's substrate interactions using site-directed mutagenesis.
    Leung LL; Hall SW
    Trends Cardiovasc Med; 2000 Feb; 10(2):89-92. PubMed ID: 11150736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review.
    Sillen M; Declerck PJ
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
    Binette TM; Taylor FB; Peer G; Bajzar L
    Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T; Nakamura T; Kakutani H; Ishii H
    Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory and anti-fibrinolytic effects of thrombomodulin alfa through carboxypeptidase B2 in the presence of thrombin.
    Tawara S; Sakai T; Matsuzaki O
    Thromb Res; 2016 Nov; 147():72-79. PubMed ID: 27693845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.